Navigation Links
Molecular Vision and Acrongenomics Unable to Reach Agreement on the Acquisition of Molecular Vision
Date:4/8/2008

LONDON, April 8 /PRNewswire/ -- The Board of Molecular Vision today announces that discussions with Acrongenomics on the proposed acquisition of Molecular Vision have now ceased. Acrongenomics has been unable to complete on the terms and timetable agreed. Given this, the Board of Molecular Vision believes that the best interests of the company are served by bringing these discussions to a conclusion. Acrongenomics remains a significant shareholder in Molecular Vision, having recently acquired a 10.9% stake in the company, and work continues on the joint development agreement between the two companies that commenced in March 2006.

About Molecular Vision Limited

Molecular Vision is developing low cost easy-to-use credit-card sized devices for medical testing that will greatly extend the in-house tools available to the general practitioner. The devices are being developed to allow near patient quantitative diagnosis, currently focusing on key areas of high disease burden, namely kidney function and cardiovascular disease. The technology also has additional applications outside the diagnostics market (e.g. forensic science, homeland security and environmental monitoring).

For more information contact:

Molecular Vision

Dr. Ian Campbell

CEO

+44-207-594-1430


'/>"/>
SOURCE Molecular Vision Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
2. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
4. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
5. Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique
6. Former Pfizer Director of Inflammation Molecular Sciences to Spearhead Velcura Therapeutics Inflammatory Disease Initiatives
7. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Center for Molecular Medicine One of the First Midwest Labs to Offer Advanced Test for Patients with Metastatic Breast Cancer
10. Delivering Molecular Imaging Solutions Across Clinical Specialties: Siemens Showcases New Technologies at RSNA 2007
11. Center for Molecular Medicine Offers Xceed Ziplex(TM) Services to Research Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... ... Food and Drug Administration (FDA) inspection at our Dilworth, MN site. The inspection ... issued. This inspection was conducted as part of a routine Bioresearch Monitoring Program ...
(Date:8/15/2017)... After spending the past two years building a state-of-the-art technology which ... offers this platform to healthcare stakeholders (hospitals, foundations, biopharma companies etc.) ... collection vis a vis their members, under their own brand. Three ... offer. ... ...
(Date:8/15/2017)... ... August 15, 2017 , ... Pittcon is ... for analytical and scientific instruments. This year’s symposium, organized by the Pittcon 2018 ... Spectrometry for Bioanalytical Applications.” This dynamic presentation will discuss novel ionization processes, high ...
(Date:8/15/2017)... ... August 15, 2017 , ... The Conference Forum ... 360° (IO360°) programming through a series of upcoming panels and events. The partnership culminates ... at The Roosevelt Hotel in New York City. , “With our experience in producing ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
Breaking Biology News(10 mins):